Abstract:Purpose: Pancreatic cancer patients respond very poorly to currently available chemotherapeutic agents partly due to the high degree of inherent and acquired chemo-resistance. We recently reported the potential efficacy of Thymoquinone (TQ), present in the volatile oil of the seed Nigella sativa (also called black cumin seeds) in chemosensitizing pancreatic cancer cells in vitro (Banerjee S et.al. 2008 AACR Annual Meeting, San Diego, Abstract # 712). As corollary to our initial findings, we further investigated whether thymoquinone could sensitize pancreatic tumors to conventional cytotoxic agents in vivo using an orthotopic mouse model of pancreatic cancer. Methods: Female ICR-SCID mice orthotopically implanted with HPAC tumor cells were randomized into 6 treatment groups comprising (n = 5-7): (a) untreated control; (b) TQ only (50 mg/kg b.wt/day orally by gavage for 30 days); (c) gemcitabine alone (50 mg/kg b.wt; 2x/wk.); (d) oxaliplatin alone (5 mg/kg b.wt; 2x/wk.; and (e) TQ followed by gemcitabine/oxaliplatin. Molecular evidence in support of chemosensitization of pancreatic tumors to oral TQ treatment was assessed by performing gel shift assay for NF-κB DNA binding activity, and assessed the expression of NF-κB dependent downstream genes such as survivin and Bcl-xL by Western blot analysis. Additionally, chemosensitization was validated in vivo using non invasive optical imaging of EGF receptor expression as biomarker in addition to tumor weight measured at the time of sacrifice of all the experimental animals. Results: Analysis of average pancreatic tumor weight in different treatment groups revealed that pre-treatment with TQ followed by gemcitabine and/or oxaliplatin resulted in a significant reduction in tumor weight relative to untreated control (p < 0.05) and in single regimen treated animals. In parallel with our in vitro findings, we confirmed in an in vivo animal model the potential of TQ in augmenting down-regulation of NF-κB (which contributes to cytotoxic chemotherapeutic drug induced chemo-resistance), resulting in the sensitization of tumor cell to greater killing by cytotoxic agents. Using non invasive optical imaging of EGF receptor as representative of tumor size, we found that this method yields low tissue auto-fluorescence corroborating other parameters predictive of chemo-sensitization for assessing the therapeutic efficacy of both gemcitabine and oxaliplatin.

Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone

Emodin Sensitizes the Gemcitabine-Resistant Cell Line Bxpc-3/Gem to Gemcitabine Via Downregulation of NF-κB and Its Regulated Targets.

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

In Vivo Molecular Evidence for Enhanced Chemosensitivity of Pancreatic Cancer Cells to Gemcitabine and Oxaliplatin by Thymoquinone

Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells.

Activation of 5-Lipoxygenase is Required for Nicotine Mediated Epithelial-Mesenchymal Transition and Tumor Cell Growth

Effects of chronic nicotine on the autocrine regulation of pancreatic cancer cells and pancreatic duct epithelial cells by stimulatory and inhibitory neurotransmitters

The Tobacco Metabolite NNK Enhances Pancreatic Cancer Cell Stemness and Chemoresistance by Activating the Β2ar-Akt Autophagy Axis

Nicotine Induces Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Epithelial Ductal Cells.

Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway

Nicotinamide Prohibits Proliferation and Enhances Chemosensitivity of Pancreatic Cancer Cells Through Deregulating Sirt1 and Ras/Akt Pathways

NNK from Tobacco Smoking Enhances Pancreatic Cancer Cell Stemness and Chemoresistance by Creating a Β2ar‐akt Feedback Loop That Activates Autophagy

Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro, and In Vivo Evaluations

Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer

Hypoxia Potentiates Gemcitabine-Induced Stemness in Pancreatic Cancer Cells Through AKT/Notch1 Signaling

Hedgehog Signaling Pathway Mediates Gemcitabine Intrinsic Chemoresistance in Pancreatic Cancer

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression

Addressing Chemoresistance with a Lipid Gemcitabine Nanotherapeutic Strategy for Effective Treatment of Pancreatic Cancer

Nicotine Promotes Tumor Progression and Epithelial-Mesenchymal Transition by Regulating the Mir-155-5p/ndfip1 Axis in Pancreatic Ductal Adenocarcinoma.

Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition

(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells